検査と技術51巻6号

2023年06月発行

疾患と検査値の推移

脂肪肝（NASH，NAFLDを含む）—診断法および検査値と画像所見の推移

著者： 和久井紀貴¹ 松井哲平¹ 永井英成¹

所属機関： ¹東邦大学医療センター大森病院消化器内科

ページ範囲：P.658 - P.663

Point

●脂肪肝の診断は主に超音波検査で行われており，Bモード法と併せ，脂肪減衰イメージングが活用されている．

●脂肪肝のなかでも飲酒を伴わないNAFLDのうち，線維化が進行し肝硬変や肝癌のリスクがあるNASHが注目されている．

●NASHの治療法は食事・運動による減量や薬物療法である．現在のところ，特に減量が最も効果的な治療法とされている．

参考文献

1）Joseph AE, et al. Ultrasound in the detection of chronic liver disease (the “bright liver”). Br J Radiol. 1979; 52: 184-188.

2）Yajima Y, et al. Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J Exp Med. 1983; 139: 43-50.

3）Dasarathy S, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009; 51: 1061-1067.

4）Bohte AE, et al. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011; 21: 87-97.

5）Hernaez R, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-1090.

6）Hamaguchi M, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007; 102: 2708-2715

7）Denpo H, et al. Re-examination of B-mode images of fatty changes in the liver-a comparison with the non alcoholic fatty liver disease activity score. Jpn J Med Ultrasonics. 2015; 42: 337-345.

8）Targher G, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-1218.

9）Urena MA, et al. An approach to the rational use of steatotic donor livers in liver transplantation. Hepatogastroenterology 1999; 46: 1164-1173.

10）Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.

11）Ogino Y, et al. The ultrasound-guided attenuation parameter is useful in quantification of hepatic steatosis in non-alcoholic fatty liver disease. JGH Open. 2021; 5: 947-952.

12）Saadeh S, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750.

13）Hyodo T, et al. Multimaterial decomposition algorithm for the quantification of liver fat content by using fast-kilovolt-peak switching dual-energy CT: clinical evaluation. Radiology 2017; 283: 108-118.

14）Vilar-Gomez E, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149: 367-378.e5.

15）Sanyal AJ, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362: 1675-1685.